Generic Name and Formulations:
Ziconotide acetate 25mcg/mL, 100mcg/mL; soln for intrathecal infusion; preservative-free.
Jazz Pharmaceuticals plc
Indications for PRIALT:
Management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment (eg, systemic analgesics, adjunctive therapies, intrathecal morphine).
Give by intrathecal infusion using appropriate microinfusion device and procedures. Individualize; see literature. Initial: up to 2.4mcg/day (0.1microgram/hr); titrate in increments of up to 2.4mcg/day (0.1mcg/hr) at intervals of up to 2–3 times per week; max 19.2mcg/day (0.8mcg/hr) by day 21.
History of psychosis. Inj site infections. Uncontrolled bleeding diathesis. Spinal canal obstruction.
Risk of severe psychiatric symptoms and neurological impairment. Monitor for signs/symptoms of meningitis and other infections. Discontinue if infection, cognitive impairment, hallucinations, mood changes, or impaired consciousness occur. Reduce dose or discontinue if myasthenias, myalgia, or persistent increases in serum creatine kinase occur. Hepatic or renal impairment. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant intrathecal opiates: not recommended. CNS effects potentiated by other CNS depressants, antiepileptics, neuroleptics, diuretics; discontinue ziconotide if occurs.
Analgesic (non-opioid N-type calcium channel blocker).
Dizziness, GI upset, fever, headache, somnolence, nystagmus, asthenia, ataxia, abnormal vision, dysesthesia, parasthesia, urinary retention, psychiatric effects (eg, hallucinations, mania), cognitive/memory impairment (eg, confusion, aphasia, stupor), worsening depression/suicidal ideation.
Soln single-use vial; 25mcg/mL (20mL)—1; 100mcg/mL (1mL, 5mL)—1
Neurology Advisor Articles
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- A Convenient Truth: The Problem With Seizure Under-Reporting and How to Fix It
- Incidence of Serotonin Syndrome With Co-Prescription of Triptans, Antidepressants
- Idiopathic Parkinson Disease May Increase Risk for Overactive Bladder
- Palliative Care in Movement Disorders: Recommendations for Improvement
- Cannabinoids May Be Effective as Adjunctive Treatment for Refractory Epilepsy